Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 618

2.

Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context.

Neyt M, Thiry N, Ramaekers D, Van Brabandt H.

Appl Health Econ Health Policy. 2008;6(1):67-80.

PMID:
18774871
3.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

4.

Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.

Sanders GD, Kong MH, Al-Khatib SM, Peterson ED.

Am Heart J. 2010 Jul;160(1):122-31. doi: 10.1016/j.ahj.2010.04.021.

PMID:
20598982
5.

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.

Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA.

Ann Intern Med. 1997 Jan 1;126(1):1-12.

PMID:
8992917
6.

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.

Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK.

Ann Intern Med. 2001 Nov 20;135(10):870-83.

PMID:
11712877
7.

Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

Cuoco FA, Spencer WH 3rd, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR.

J Am Coll Cardiol. 2008 Nov 18;52(21):1718-23. doi: 10.1016/j.jacc.2008.07.061.

8.

The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.

Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG.

Eur Heart J. 2007 Jan;28(1):42-51. Epub 2006 Nov 16.

PMID:
17110403
9.

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):440-8.

PMID:
12228780
10.

Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.

O'Brien BJ, Buxton MJ, Rushby JA.

Br Heart J. 1992 Aug;68(2):241-5.

11.

Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.

Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S.

J Am Coll Cardiol. 2006 Jul 4;48(1):112-21. Epub 2006 Jun 9.

12.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
13.

Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias.

Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):67-83.

PMID:
16274418
14.

[14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].

Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.

Z Kardiol. 2000;89 Suppl 3:194-205. German.

PMID:
10810803
15.

Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.

Deniz HB, Ward A, Jaime Caro J, Alvarez P, Sadri H.

Curr Med Res Opin. 2009 Mar;25(3):617-26. doi: 10.1185/03007990802695037 .

PMID:
19232036
16.

Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH; SCD-HeFT Investigators.

Circulation. 2006 Jul 11;114(2):135-42. Epub 2006 Jul 3.

17.

Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.

Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM.

Int J Technol Assess Health Care. 2009 Apr;25(2):151-60. doi: 10.1017/S0266462309090205. Epub 2009 Mar 31.

PMID:
19331707
18.

Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.

Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, de Roy L, Heidbuchel H, Verboven Y, Braunschweig F, Linde C, Boriani G.

Europace. 2009 Jun;11(6):716-26. doi: 10.1093/europace/eup068. Epub 2009 Apr 9.

PMID:
19359333
19.

Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.

Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1.

PMID:
20132378
20.

Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy.

Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG.

J Am Coll Cardiol. 1992 May;19(6):1323-34.

Supplemental Content

Support Center